Search academic texts

Information × Registration Number 0217U000685, 0114U001064 , R & D reports Title To investigate the efficacy of radionuclide therapy samarium 153Sm oksabiforom metastatic bone lesions in malignant tumors of different localization popup.stage_title Head Solodyannikova Oksana Ivanovna, Registration Date 21-02-2017 Organization Ukrainian Research Institute of Oncology and Radiology popup.description2 An object of investigation is 150 patiens with a metastatic bones. A purpose is investigation - to find efficiency of treatment and define the place of radionuklidnoy therapy the samarium of oksabiforom 153Sm in treatment of metastatic bones at the malignant tumours of different localization. Methods and apparatures are a hool body scan with 99mTc-MDP, hool body scan with the samarium of oksabiforom 153Sm, dynamic scintigraphy with the samarium of oksabiforom 153Sm, statistical; two-head. It is set that radionuklide therapy with the samarium of oksabiforom 153Sm can be used in the holiatry of metastatic of bones at the malignant tumours of different localization. It is set that 153Sm is characterized the high level of accumulation of RFP in a metastatic and minimum side effects. Before treatment intensity of pain syndrome (in accordance with the scale of "LAKOMED") corresponded 7-9 marks at most patients. After the finished treatment. Most effective by comparison to 32R and 89Sr in treatment of bone metastases an antianalgezives action and toxicity of preparation is a samarium of oksabifor 153sm (r<0,05). The angiocardiograms with the samarium of oksabiforom 153sm from bone metastases which accumulate RFP intensively, there is a brief descending segment or his absence and transition of ascending segment at once in a plateau or slowly ascending segment. The dynamic curves "activity-time", from bone metastases which amass RFP, as a rule, have ascending character, speed of high of curves can testify to efficiency of course of radionuklid therapy. According to the initial pharmakokinetics of 153sm-oksabifora, a leadthrough of scan-out of all body for the estimation of process is optimum through 1-1,5 hour and later after intravenous injection of RFP. Product Description popup.authors Даниленко Вікторія Вікторівна Джужа Дмитро Олександрович Міхайленко Валерій Євгенович Сукач Георгій Георгійович popup.nrat_date 2020-04-02 Close